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ABSTRACT
Objective The colonic microbiota ferment dietary
fibres, producing short chain fatty acids. Recent evidence
suggests that the short chain fatty acid propionate may
play an important role in appetite regulation. We
hypothesised that colonic delivery of propionate would
increase peptide YY (PYY) and glucagon like peptide-1
(GLP-1) secretion in humans, and reduce energy intake
and weight gain in overweight adults.
Design To investigate whether propionate promotes
PYY and GLP-1 secretion, a primary cultured human
colonic cell model was developed. To deliver propionate
specifically to the colon, we developed a novel inulin-
propionate ester. An acute randomised, controlled cross-
over study was used to assess the effects of this inulin-
propionate ester on energy intake and plasma PYY and
GLP-1 concentrations. The long-term effects of inulin-
propionate ester on weight gain were subsequently
assessed in a randomised, controlled 24-week study
involving 60 overweight adults.
Results Propionate significantly stimulated the release
of PYY and GLP-1 from human colonic cells. Acute
ingestion of 10 g inulin-propionate ester significantly
increased postprandial plasma PYY and GLP-1 and
reduced energy intake. Over 24 weeks, 10 g/day inulin-
propionate ester supplementation significantly reduced
weight gain, intra-abdominal adipose tissue distribution,
intrahepatocellular lipid content and prevented the
deterioration in insulin sensitivity observed in the inulin-
control group.
Conclusions These data demonstrate for the first time
that increasing colonic propionate prevents weight gain
in overweight adult humans.
Trial registration number NCT00750438.
INTRODUCTION
Evidence published over the last 25 years demon-
strates that hormonal and neuronal signals from the
GI tract play an important role in appetite regula-
tion.1 There is increasing evidence that the gut
microbiota influences energy regulation and can be
a major determinant in the development of
obesity.2 Recent investigations suggest that diet, the
gut microbiota and fat storage can be linked
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Significance of this study
What is already known about this subject?
▸ Increased intake of dietary fibre has been
associated with reduced appetite and weight
loss.
▸ The short chain fatty acids (SCFAs) produced by
microbial fermentation of dietary fibre in the
colon stimulate the release of the anorectic gut
hormones peptide YY (PYY) and glucagon like
peptide-1 (GLP-1) from rodent enteroendocrine
L cells via activation of the G protein coupled
free fatty acid receptor (FFAR) 2.
▸ Of the SCFAs produced by colonic fermentation
of dietary fibre, propionate has the highest
affinity for FFAR 2.
▸ Mice receiving a faecal transplant from a donor
with a gut microbiota composition that
produces elevated levels of propionate in the
colon have reduced weight gain and adiposity.
What are the new findings?
▸ Propionate stimulates the release of PYY and
GLP-1 from primary cultured human colonic
cells.
▸ This first-in-human study demonstrates that
delivery of propionate directly to the colon,
acutely increases the release of PYY and GLP-1
and reduces energy intake.
▸ Long-term colonic propionate delivery prevents
body weight gain and reduces intra-abdominal
fat accretion in overweight adults.
▸ Long-term colonic propionate delivery
significantly reduces intrahepatocellular lipid
content in adults that meet the diagnostic
criteria for non-alcoholic fatty liver disease.
How might it impact on clinical practice in
the foreseeable future?
▸ Optimising colonic propionate production
through selection of propiogenic dietary fibres
may represent a novel route to prevent weight
gain throughout life and improve public
health.
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through a molecular mechanism involving short chain fatty
acids (SCFAs), the major products of dietary fibre fermentation
by the gut microbiome.3–5
A major public health challenge is the development of effect-
ive strategies that can prevent the increased prevalence in
obesity and the reported average 0.3–0.8 kg/year weight gain in
adults.6–9 Such gradual long-term weight gain can be the result
of a small habitual positive energy balance of 50–100 kcal/day.10
Interventions that can be safely applied at the population level
to reverse this minor energy imbalance and prevent weight gain
throughout life would therefore have substantial benefits to
public health. Increased intake of dietary fibre has been asso-
ciated with reduced appetite and weight loss.11–13 In particular,
evidence suggests that the fermentable component of dietary
fibre is critical in mediating these satiating effects.14 Feeding
rodents a high level of fermentable dietary fibre protects against
high-fat, diet-induced increases in body weight and fat
mass.15 16 There is also evidence that fermentable dietary fibre
can suppress appetite and decrease body weight in humans.17–19
However, large amounts of dietary fibre (>30 g/day) are
required for these beneficial effects, and compliance with high
fibre diets is poor, due to GI side effects, which may also
explain the inconsistent reports regarding their effects on appe-
tite and body weight.20 Targeting the mechanisms by which fer-
mentable dietary fibre suppresses appetite may thus provide a
more effective approach to weight control than the use of high
fibre diets.
The SCFAs produced by microbial fermentation of dietary fibre
in the colon have been shown to stimulate the release of the anor-
ectic gut hormones peptide YY (PYY) and glucagon like peptide-1
(GLP-1) from rodent enteroendocrine L cells.21–23 These hor-
mones are released from the gut and are involved in the short-term
signal of satiation and satiety to the appetite centres of the brain.24
Peripheral administration of PYY3–36 or GLP-1 enhances satiety
and reduces food intake in animals and man.25–27 Recent evidence
suggests that SCFAs stimulate GLP-1 release in rodents via stimula-
tion of the G protein coupled free fatty acid receptor (FFAR) 2 on
colonic L cells.21 Of the SCFAs produced by colonic fermentation
of dietary fibre, propionate has the highest affinity for
FFAR 2.28 29 Furthermore, propionate is an end product of bacter-
ial metabolism, and thus, unlike acetate, does not undergo conver-
sion to other SCFAs.30 Intriguingly, Roux-en-Y gastric bypass,
which results in weight loss and reduced adiposity, promotes
increased levels of propionate in the colon.5 In keeping with these
findings, a significant negative correlation between adiposity and
caecal propionate concentrations has also been reported in germ-
free mice receiving faecal transplants from human twin donors dis-
cordant for obesity.4
Increasing colonic propionate is therefore an attractive target
for appetite modulation. However, orally administered SCFAs
are unpalatable and are rapidly absorbed in the small intestine
where L cells are sparse. Furthermore, supplementing diets with
mixed high fibre does not predictably or reliably increase
colonic production or circulating levels of propionate in all
human populations because of the variability in gut microbial
activity.31 To overcome the unpalatably high levels of ferment-
able dietary fibre needed to significantly increase colonic propi-
onate levels, and the unpredictability in the production of the
resulting SCFAs, we have developed a novel delivery system tar-
geting the release of gram quantities of propionate in the prox-
imal colon. We hypothesised that propionate would stimulate
anorectic gut hormone release from the colon and that targeted
delivery of propionate to the colon would decrease appetite and
prevent long-term weight gain in humans.
METHODS
In vitro gut hormone secretion experiments
The effect of propionate on PYY and GLP-1 release from human
colonic crypts was determined using a modified version of an
established method32 (see online supplementary material).
Inulin-propionate ester for colonic delivery of propionate in
humans
We developed a novel carrier molecule whereby propionate is
chemically bound by an ester bond to inulin, a natural polymer
composed mainly of fructose. This inulin-propionate ester was
synthesised, as detailed in the online supplementary material.
The majority of propionate chemically bound to inulin should
only be released when the inulin polymer is fermented by the
colonic microbiota, thus providing targeted colonic delivery.
Isotope labelling studies were conducted to assess the stability of
the molecule through the stomach and small intestine, and to
provide information about site and extent of propionate release,
as described in the online supplementary information. In add-
ition, the effects of inulin-propionate ester on fermentation pro-
files and gut microbial populations were studied using an in
vitro culture system (see online supplementary material).
Clinical studies
All subjects provided informed, written consent prior to the
clinical trial which was approved by the Hammersmith and
Queen Charlotte’s Research Ethics Committee (08/H0707/99).
All studies were carried out in accordance with the Declaration
of Helsinki. All clinical trials where registered (Registration No:
NCT00750438).
Investigation of acute supplementation with
inulin-propionate ester on appetite regulation
In first-in-human studies, the acute effects of inulin-propionate
ester on appetite regulation, hormone release and energy intake
were studied in 20 volunteers. The primary outcome was energy
intake, and gut hormone release was a secondary outcome. The
effects on gastric emptying were examined in 14 volunteers in a
separate study. Detailed inclusion and exclusion criteria and
methodology for each acute study are described in the online
supplementary material.
Proof-of-principle investigation of the effect of long-term
supplementation with inulin-propionate ester on body
weight maintenance
We hypothesised that daily intake of inulin-propionate ester over
24 weeks would decrease weight gain in overweight adults. The
predefined coprimary outcomes were changes in body weight
and food intake. A change in adipose tissue distribution was a
secondary outcome. Men and women aged 40–65 years, with a
body mass index (BMI) of 25–40 kg/m2 were recruited. Potential
participants were excluded if they met any of the following cri-
teria: clinically significant illness (including type 1 or type 2 dia-
betes), medication known to affect appetite and/or body weight,
a weight loss of 3 kg or greater in the preceding 2 months,
smoking, substance abuse, psychiatric illness and any abnormal-
ities detected on physical examination, electrocardiography or
screening blood tests (measurement of complete blood count,
electrolytes, fasting glucose, thyroid function and liver function).
Women were ineligible if they were pregnant or breast feeding.
From an initial 167 persons who responded to letters of invita-
tion, 60 were randomly assigned to either the inulin-control or
inulin-propionate ester supplementation group.
Gut microbiota
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Study design
The study was conducted using a randomised, double-blind,
placebo-controlled, parallel design. Two-day study visits were
required at baseline (week 0) and after 24 weeks of dietary sup-
plementation. On the day prior to each study visit, subjects were
asked to consume a standard evening meal, to fast overnight
from 22:00 and to avoid strenuous physical activity and alcohol.
All study visits commenced between 08:00 and 09:00 and were
conducted at the National Institute for Health Research (NIHR)/
Wellcome Trust Imperial Clinical Research Facility. After all base-
line measurements had been taken, subjects were randomly
assigned to either the 10 g/day inulin-propionate ester group, or
the 10 g/day inulin-control group. Subjects were randomised as
described in the online supplementary material. The dietary sup-
plement was supplied to subjects in ready-to-use sachets and they
were instructed to mix the contents into their normal diet once a
day during the 24-week supplementation period. All subjects
were instructed to maintain their usual dietary and physical activ-
ity habits during the supplementation period. Self-reported food
intake and physical activity were assessed at baseline and after
24 weeks of supplementation (see online supplementary
material). Regular communication between subjects and study
investigators encouraged good compliance. At week 8 and week
16 of the supplementation period, subjects attend follow-up
visits to monitor compliance and adverse events. At week 24,
measurements taken at baseline were repeated. Subjects returned
all their used and unused sachets to estimate compliance.
Body weight and composition
Body weight was measured in all subjects to the nearest 0.1 kg
(Tanita BC-418MA) while subjects were wearing light clothing.
Body composition was assessed using MRI and MR spectroscopy
(MRS), as previously described.33 MRI and MRS data could not
be collected in 20 subjects, due to metal implants (n=8), claustro-
phobia (n=9) or technical issues with the scanner (n=3).
Appetite regulation, gut hormone release and glucose
homoeostasis
A cannula was inserted into an antecubital vein and baseline blood
samples collected at −10 min and 0 min to assess plasma concen-
trations of glucose, insulin, PYY and GLP-1. Following the 0 min
sample, subjects were served a standardised breakfast (398 kcal;
71.2 g carbohydrate, 7.9 g fat, 10.3 g protein). At week 24, the
breakfast also contained 10 g of inulin-propionate ester or 10 g
inulin-control depending on supplementation group. Postprandial
blood samples were taken at 15 min, 30 min, 60 min, 90 min,
120 min, 180 min, 240 min and 300 min and collected into
heparin-coated tubes containing 0.2 mL of aprotinin (Bayer, UK).
GLP-1-like and PYY-like immunoreactivity were measured using
established inhouse radioimmunoassay.34 35 Insulin and leptin
were measured by radioimmunoassay using commercially available
kits (Millipore, USA). Plasma glucose was measured using an
Abbott Architect ci8200 analyser (Abbott Diagnostics, USA). At
300 min subjects were offered a buffet lunch with food served in
excess, and asked to eat until they felt comfortably full. The
amount of food was quantified and energy intake calculated.
Subjective hunger, satiety and nausea were monitored with the use
of 100 mm visual analogue scales (VAS).36 Subjects were asked to
complete the VAS before each blood sample.
Risk factors for cardiovascular disease and diabetes
A fasting blood sample was collected and analysed for levels of
triglycerides, total cholesterol, low-density lipoprotein
cholesterol, high-density lipoprotein cholesterol, glycosylated
haemoglobin (HbA1c), C reactive protein and liver function
tests (alanine transaminase, alkaline phosphatase, aspartate
transaminase). All analytes were measured by the Department of
Chemical Pathology, Imperial College Healthcare National
Health Service Trust. Blood pressure and pulse were also mea-
sured after subjects had been in a supine position for at least
15 min.
Statistical analysis
The treatment group size for the acute energy intake study was
based on a power calculation, assuming a decrease of 15% in
energy intake with a SD of 20% (α=0.05, power=0.85), result-
ing in an estimated required sample size of 20 subjects. Data
from the acute supplementation study suggested a sample size of
50 individuals (25 in each group) was needed for the long-term
investigation. Sixty volunteers were therefore recruited to allow
for an estimated attrition rate of 15%. χ2 tests were performed
to compare percentages of subjects in each group who gained
≥3% and ≥5% of their initial weight. For comparison of vari-
ables with a single measurement pre supplementation and post
supplementation, we calculated the change from baseline at
24 weeks and compared means within groups using paired
t-tests. The mean changes between groups for each of these vari-
ables were estimated using a multiple linear regression adjusted
for its baseline measurement, baseline weight and randomised
group. The linear model was also run on logit-transformed vari-
ables that were expressed as percentages to ensure their predict-
ive values are within the 0–100% range.37 Variables measured
multiple (>2) times during the supplementation period (body
weight, postprandial glucose, postprandial insulin response, PYY,
GLP-1, VAS, side effects assessment) were analysed using multi-
level mixed effects models to account for the variability within
and between subjects. Area under the curve (AUC), unadjusted
for covariates, for postprandial glucose and postprandial insulin
response, was also calculated and compared between groups. In
the case of data missing at random, the regression techniques
described previously were applied after data were imputed using
the multiple imputation by chained equations technique to
account for random biases of the unobserved covariates. Data
are presented as mean±SEM or 95% CI. p Values <0.05 were
considered statistically significant.
RESULTS
Propionate stimulates PYY and GLP-1 release from human L
cells in vitro
Propionate significantly stimulated PYY secretion from human
colonic cells, with concentrations of 200 mmol/L and
400 mmol/L inducing 1.8-fold and threefold rises above basal
secretion, respectively (p<0.05 and p<0.001; figure 1A).
Propionate also increased GLP-1 secretion, with 200 mmol/L
and 400 mmol/L inducing 1.6-fold and 2.4-fold increases in
GLP-1 release, respectively (p<0.001; figure 1B).
Inulin-propionate ester delivers propionate to the colon
Propionate production from in vitro faecal fermentations was
significantly higher from inulin-propionate ester compared with
inulin, while no significant differences in acetate or butyrate
production were observed (see online supplementary figure S1).
Following ingestion of 10 g inulin-propionate ester, breath H2
started to increase at 180 min and peaked at 240 min post inges-
tion. A small gradual release of 13C was apparent between 0
min and 180 min post ingestion. More than 80% (82.9±2.3%)
of the 13C recovered in breath over 24 h appeared coincident
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with and after breath H2 onset (figure 1C), suggesting delivery
of the majority of the tracer to the colon. It is estimated that
10 g inulin-propionate ester delivered 2.36 g propionate to the
colon after accounting for small intestinal losses (0.49 g). The
isotopic data show that propionate released from the inulin-
propionate ester appeared in the blood and was thus available
systemically. Where circulating plasma propionate was detect-
able, significant increases in propionate 13C enrichment and
total concentration were measured in peripheral blood 360 min
post ingestion compared with baseline (figure 1D, E). No
significant differences were observed in plasma acetate enrich-
ment or total concentration (figure 1D, F). We estimate that the
addition of 10 g inulin-propionate ester to the diet would lead
to a 2.5-fold increase in daily colonic propionate production
(see online supplementary material).
Acute supplementation with inulin-propionate ester
increases PYY and GLP-1 secretion and reduces food intake
Acute supplementation with inulin-propionate ester signifi-
cantly reduced food intake from 1175 kcal (95% CI 957 to
Figure 1 Propionate increases peptide YY (PYY) and glucagon like peptide-1 (GLP-1) release from primary human colonic cells and
inulin-propionate ester supplementation delivers propionate to the colon in vivo. Cells isolated from human colonic tissue were incubated with
increasing concentrations of propionate. (A) PYY and (B) GLP-1 levels were measured in the supernatants and lysed cells by radioimmunoassay.
Percentage gut hormone release per well is expressed relative to the basal release measured (n=4–6). (C) The increase in breath H2 at 240 min
suggests that >80% of the labelled propionate entered the colon. (D) Plasma acetate and propionate 13C enrichment (δ13C per mil) at baseline and
360 min. Plasma propionate was significantly more enriched at 360 min whereas no difference was seen in acetate enrichment. Total plasma
propionate (E) and acetate (F) concentrations (mmol/L) at baseline and 360 min. Data are presented as mean±SEM, *p<0.05, ***p<0.001.
Gut microbiota
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1392) to 1013 kcal (95% CI 816 to 1210) (figure 2A, B;
p<0.01), a mean reduction of 13.8%. It takes an estimated
240 min for the inulin-propionate ester to enter the colon
(figure 1C) and compared with inulin-control, inulin-
propionate ester significantly increased plasma PYY (ΔAUC240–
420 min 429 min×pmol/L (95% CI −543 to 1400) inulin-
control vs 3349 min×pmol/L (841 to 5857) inulin-propionate
ester, p<0.05) and GLP-1 levels (ΔAUC240–420 min 3495
min×pmol/L (95% CI −1567 to 8558) inulin-control vs 10
801 min×pmol/L (5897 to 15 704) inulin-propionate ester,
p<0.05) between 240 min and 420 min. Prior to 240 min
there was no significant difference in the concentration of PYY
and GLP-1 between the inulin-control and the inulin-
propionate ester (figure 2D). Glucose, insulin and leptin levels
and subjective ratings of appetite and nausea were not signifi-
cantly different following acute inulin-propionate ester and
inulin-control supplementation (see online supplementary
figures S2 and S3). Acute supplementation with inulin-
propionate ester did not influence the rate of gastric emptying
(see online supplementary information).
Figure 2 Acute inulin-propionate ester supplementation increases plasma peptide YY (PYY) and glucagon like peptide-1 (GLP-1) levels and reduces
energy intake in humans. (A) The mean reduction in energy intake following inulin-control versus inulin-propionate ester. (B) A reduction in energy
intake occurred in 16 of the 20 volunteers. (C–F) Plasma gut hormone levels following acute supplementation of inulin-control versus
inulin-propionate ester. Arrows indicate standardised meals. Dotted lines signify the time point after which >80% inulin-propionate ester enters the
colon as determined by the enrichment of 13C in expired air and breath H2 methodology (figure 1C). Data are presented as mean±SEM, *p<0.05,
**p<0.01. AUC, area under the curve.
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Long-term supplementation with inulin-propionate ester
prevents body weight gain, intra-abdominal adipose tissue
accretion and reduces intrahepatocellular lipid content in
those with non-alcoholic fatty liver disease
Of the 60 volunteers randomised, data were analysed from the
49 participants that completed the 24 week supplementation
(table 1). Eleven participants (18%) did not complete the
24 week supplementation and there were no significant differ-
ences in attrition between the two groups (see online supple-
mentary figure S4). Baseline and postsupplementation body
composition data was collected from 17 participants in the
inulin-propionate ester group and 15 participants in the inulin-
control group. There was no difference between groups in com-
pliance (95% (95% CI 92% to 98%) inulin-propionate ester vs
94% (95% CI 92% to 97%) inulin-control; p=0.864). Ratings
of nausea were not different between supplementation groups
(p=0.736), though there were significantly greater ratings of
flatulence (p=0.004) in the inulin-control group during the sup-
plementation period compared with the inulin-propionate ester
group (see online supplementary table S1).
Body weight and composition
Inulin-propionate ester supplementation resulted in beneficial
changes in body weight and composition. There was a signifi-
cant difference in weight gain between groups. One of 25
participants gained ≥3% of their baseline body weight following
inulin-propionate ester supplementation (4%), as compared
with 6 of 24 participants (25%) in the inulin-control group
(figure 3A, p=0.036). Furthermore, none of the participants in
the inulin-propionate ester group had substantial weight gain
(≥5% baseline weight) compared with 4 of 24 (17%) following
inulin-control supplementation (figure 3A; p=0.033). Although
the primary aim of the study was to prevent weight gain, it is of
interest to note that weight loss after 24 weeks was greater in
the propionate ester group, though this effect was not signifi-
cantly different between groups (0.38 kg (95% CI −0.95 to
1.72) inulin-control vs −1.02 kg (95% CI −2.10 to 0.04) propi-
onate ester, p=0.099). Following the supplementation period,
the change in the distribution of intra-abdominal adipose tissue,
expressed as a percentage of total adipose tissue content, was
significantly lower in the inulin-propionate ester group com-
pared with inulin-control supplementation (table 2; p=0.027).
Furthermore, internal adipose tissue (p=0.002) and the ratio of
internal adipose tissue: subcutaneous adipose tissue was signifi-
cantly increased within the inulin-control group (p=0.002), but
not in the inulin-propionate ester group. There was no signifi-
cant change in total adipose tissue content between groups.
Within the inulin-propionate ester group there was a trend for
reduced intrahepatocellular lipid (IHCL) content post supple-
mentation (p=0.061). However, subjects meeting the baseline
diagnostic criteria for non-alcoholic fatty liver disease (NAFLD)
Table 1 Baseline characteristics of subjects and changes in cardiovascular and diabetes risk factors following 24 weeks of inulin-control and
inulin-propionate ester supplementation
Variable
Inulin-control (N=24) Inulin-propionate ester (N=25) Inulin-propionate Ester−inulin-control
p ValueWeek 0 Week 24 Value Week 0 Week 24 p Value Difference (95% CI)
Sex (% no. of subjects)
Male 37.5 (9) 40.0 (10)
Female 62.5 (15) 60.0 (15)
Race or ethnicity (% no. of subjects)
White 75.0 (18) 64.0 (16)
Black 8.3 (2) 16.0 (4)
Asian 17.7 (4) 20.0 (5)
Age (years) 53.4±1.5 55.3±1.4
Weight (kg) 91.0±2.8 91.4±3.0 0.559 88.5±2.9 87.5±3.0 0.062 −1.40 (−3.07 to 0.27) 0.099
Glucose (mmol/L) 5.1±0.1 5.0±0.1 0.624 5.0±0.1 5.0±0.1 0.898 0.05 (−0.21 to 0.32) 0.675
Insulin (mU/mL) 11.5±1.3 10.6±0.7 0.329 9.0±1.0 8.8±0.8 0.702 −0.56 (−2.64 to 1.51) 0.582
HOMA-IR 2.7±0.3 2.3±0.2 0.372 2.0±0.2 2.0±0.2 0.644 0.14 (−0.63 to 0.34) 0.549
HbA1c (mmol/mol) 37.8±0.5 37.1±0.5 0.086 38.2±0.7 37.8±0.7 0.297 0.18 (−0.85 to 1.21) 0.729
Triglycerides (mmol/L) 1.5±0.2 1.6±0.2 0.283 1.5±0.2 1.4±0.2 0.176 −0.29 (−0.68 to 0.11) 0.148
Cholesterol (mmol/L)
Total 5.3±0.2 5.0±0.2 0.014 5.5±0.2 5.1±0.2 <0.001 −0.10 (−0.39 to 0.19) 0.494
Low-density lipoprotein 3.3±0.2 3.1±0.2 0.132 3.5±0.2 3.2±0.2 <0.001 −0.08 (−0.34 to 0.18) 0.532
High-density lipoprotein 1.4±0.1 1.3±0.1 <0.001 1.4±0.1 1.3±0.1 0.009 0.02 (−0.06 to 0.10) 0.617
Liver function tests (IU/L)
Alanine transaminase 32.4±3.9 25.9±3.3 0.001 29.5±3.2 23.7±2.2 0.015 −0.28 (−9.30 to 8.75) 0.949
Alkaline phosphatase 78.2±3.4 71.7±3.5 <0.001 74.6±3.7 70.5±3.3 <0.001 1.41 (−2.40 to 5.22) 0.458
Aspartate transaminase 29.8±1.6 28.7±3.0 0.543 28.9±1.3 26.2±1.0 0.007 −1.43 (−7.41 to 4.55) 0.627
Leptin (ng/mL) 31.9±4.0 33.3±4.5 0.690 25.1±3.0 24.1±2.4 0.625 −2.36 (−10.31 to 3.92) 0.551
C reactive protein (mg/L) 3.7±0.5 3.7±0.6 0.818 2.1±0.4 1.8±0.3 0.484 −0.27 (−1.39 to 0.84) 0.622
Blood pressure (mm Hg)
Systolic 137±2 137±3 0.707 140±3 139±2 0.659 −0.83 (−4.98 to 3.81) 0.688
Diastolic 87±2 85±2 0.143 86±2 84±2 0.101 −0.86 (−4.92 to 3.19) 0.664
Pulse (bpm) 70±2 67±1 0.212 66±2 66±2 0.934 0.63 (−3.36 to 4.61) 0.763
Mean±SEM.
HbA1C, glycosylated haemoglobin; HOMA-IR, homoeostasis model assessment of insulin resistance.
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(IHCL >5.5%)38 had a significant reduction in IHCL content
following inulin-propionate ester supplementation (22.1% (95%
CI 7.7 to 36.6) to 15.9% (95% CI 5.2 to 26.5), p=0.038,
n=11; figure 3B). This effect was not observed in similar
subjects within the inulin-control group (19.1% (95% CI 2.0 to
36.1) to 18.7% (95% CI 7.1 to 30.3), p=0.576, n=5; figure
3B). In vitro analysis suggested that the protective effects of the
inulin-propionate ester on weight gain and adipose tissue
Figure 3 The effect of 24 weeks inulin-control and inulin-propionate ester supplementation on weight gain, liver fat content and gut hormone
response. (A) The proportion of subjects who gained 3% or more and 5% or more of their baseline weight at 24 weeks. (B) Intrahepatocellular lipid
(IHCL) content at baseline and following 24 weeks of inulin-control and inulin-propionate ester supplementation in subjects with non-alcoholic fatty
liver disease (NAFLD). Subjects were identified as having NAFLD on the basis of an IHCL content >5.5% at baseline.38 Postprandial plasma
(C) peptide YY (PYY) and (D) GLP-1 release at baseline and following 24 weeks of inulin-control and inulin-propionate ester supplementation. Data
are presented as mean±SEM, *p<0.05.
Table 2 Body fat depots at baseline and following 24 weeks of inulin-control and inulin-propionate ester supplementation
AT distribution (% total AT)
Inulin-control (N=15) Inulin-propionate ester (N=17) Inulin-propionate ester−inulin-control
p ValueWeek 0 Week 24 p Value Week 0 Week 24 p Value Difference (95% CI)
Subcutaneous AT 81.3±1.9 80.6±1.8 0.002 76.3±1.7 76.0±1.6 0.624 −0.59 (1.69 to 0.50) 0.288
Internal AT 18.7±1.9 19.4±1.8 0.002 23.7±1.7 24.0±1.6 0.624 −0.23 (−1.09 to 0.64) 0.608
Intra-abdominal AT 10.6±1.3 11.1±1.4 <0.001 13.2±1.2 13.1±1.1 0.723 −0.46 (−0.87 to −0.05) 0.027
Abdominal 23.1±0.9 22.7±0.8 0.300 21.9±0.7 21.6±0.7 0.171 −0.23 (−0.88 to 0.42) 0.483
subcutaneous AT
1H-MRS
IHCL 7.8±2.9 7.4±2.5 0.708 15.8±5.0 11.5±3.7 0.061 −0.83 (−5.04 to 3.38) 0.699
Soleus IMCL 18.8±2.0 18.8±1.8 0.973 21.8±3.0 24.0±3.7 0.274 2.70 (−1.04 to 6.44) 0.157
Tibialis IMCL 10.0±1.5 10.3±1.1 0.869 9.1±1.0 9.5±0.9 0.701 −0.42 (−2.83 to 1.99) 0.733
Mean±SEM.
IHCL was measured relative to liver water content and IMCL was measured relative to total muscle creatine signal.33
AT, adipose tissue; IHCL, intrahepatocellular lipid; IMCL, intramyocellular lipid; MRS, MR spectroscopy.
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distribution were not due to changes in gut bacterial populations
compared with inulin-control (see online supplementary
material; figure 4A–F).
Food intake and gut hormone release following long-term
supplementation with inulin-propionate ester
The change in food intake at an ad libitum meal following
24 weeks of supplementation was not statistically significant
between groups (p=0.972), though long-term inulin-propionate
ester intake showed a trend towards a lower food intake by
8.7% from 836 kcal (95% CI 724 to 948) to 763 kcal (95% CI
654 to 872) (p=0.100). Inulin-control supplementation
reduced food intake from 678 kcal (95% CI 535 to 820) to
645 kcal (95% CI 514 to 776) (p=0.197), a mean reduction of
4.0%. Subjective ratings of appetite were significantly reduced
within the inulin-propionate ester group following the supple-
mentation period, while there were no differences in ratings of
nausea (see online supplementary figure S5). Interestingly, there
were no significant differences in postprandial PYY (difference
−1.48%; 95% CI −6.29% to 3.33%; figure 3C; p=0.546) or
GLP-1 secretion (difference 3.69%; 95% CI −4.48% to
12.33%; figure 3D, p=0.361).
Glucose homoeostasis
Multilevel mixed effects models found no differences in postpran-
dial glucose (p=0.350) or insulin response (p=0.924) between
Figure 4 The effect of inulin-propionate ester on the gut microbiota. Bacterial concentrations expressed in Log10 cells/mL culture fluid enumerated
using fluorescent in situ hybridisation (FISH) targeting (A) Bifidobacterium spp (Bif164), (B) Bacteroides/Prevotella (Bac303), (C) Atopobium cluster
(Ato291), (D) Lactobacillus/Enterococcus (Lab158), (E) Clostridium histolyticum (Chis150) and (F) Eubacterium rectale/Clostridium coccoides (Erec482)
at 0 h, 10 h, 24 h, 34 h and 48 h anaerobic, pH controlled faecal batch culture fermentation with control (no substrate), inulin-control and
inulin-propionate ester. Data are presented as mean±SEM (n=3), *<0.05, †<0.001, ‡<0.0001 with respect to the 0 h sample.
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supplementation groups. However, the change in postprandial
glucose AUC to the standardised breakfast at week 24 was signifi-
cantly different between groups (see online supplementary figure
S6; p=0.037). Glycaemic response significantly deteriorated
following inulin-control supplementation (AUC0–300 min 1600
min×mmol/L (95% CI 1495 to 1705) to 1691 min×mmol/L
(95% CI 1580 to 1802), p=0.010) but remained unchanged
following inulin-propionate ester supplementation (AUC0–300 min
1630 min×mmol/L (95% CI 1534 to 1727) to 1630 min×mmol/L
(95% CI 1543 to 1717), p=0.993), in keeping with the differ-
ences in weight gain and body fat distribution observed within
the groups. Insulin AUC was not significantly different following
inulin-propionate ester (AUC0–300 min 7685 min×mU/mL (95%
CI 5858 to 9511) to 7969 min×mU/mL (95% CI 5955 to 9982),
p=0.612) or inulin-control supplementation (AUC0–300 min
9285 min×mU/mL (95% CI 7454 to 11 115) to 8781 min×mU/
mL (95% CI 7265 to 10 297), p=0.464) and the change in
insulin AUC was not significantly different between groups (see
online supplementary figure S7; p=0.372), suggesting that the
difference in glycaemic response reflects a difference in insulin
sensitivity.
Risk factors for cardiovascular disease and diabetes
Inulin-propionate ester and inulin-control supplementation sig-
nificantly reduced circulating levels of total cholesterol, high-
density lipoprotein, alanine transaminase and alkaline phosphat-
ase (table 1). Significant reductions in low-density lipoprotein
(p<0.001) and aspartate transaminase (p=0.007) were only
observed within the propionate ester group.
DISCUSSION
The GI tract is an important organ in the short-term control of
appetite.1 24 The production of SCFAs by microbial fermenta-
tion of dietary fibre has been linked to positive physiological
effects, including improvements in body weight, adiposity and
glucose metabolism.3 Our data demonstrate that the SCFA pro-
pionate stimulates the release of the anorectic gut hormones
PYY and GLP-1 from human colonic cells in vitro, supporting
observations made in animal models.21 To increase colonic pro-
pionate production in vivo, we designed and synthesised a novel
inulin-propionate ester, whereby propionate is conjugated by an
ester linkage to the carrier molecule inulin. Stable isotope meth-
odology revealed that >80% of the propionate load from the
inulin-propionate ester is released in the colon coincident with
or after a rise in breath H2. This would suggest that only a rela-
tively small amount of the esterified propionate is released and
absorbed in the small intestine. We have estimated that 10 g
inulin-propionate ester ingestion leads to a 2.5-fold increase in
daily colonic propionate production, a level very difficult to
achieve through feeding a mixed fermentable fibre diet.20 We
also demonstrated that ingestion of the inulin-propionate ester
increases plasma propionate levels.
We subsequently, in the first-in-human studies, demonstrated
that increased delivery of propionate to the colon acutely modu-
lates gut hormone release and reduces food intake in healthy
subjects. The inulin-propionate ester did not suppress subjective
appetite responses, but significantly reduced meal size, consist-
ent with the action of a physiological satiation signal. We
observed a significantly greater postprandial release of PYY and
GLP-1 when a mixed calorie breakfast contained 10 g inulin-
propionate ester compared with 10 g inulin-control. It has been
previously shown that a sustained increase in circulating PYY
and GLP-1 can influence appetite-regulating circuits of the brain
and inhibit food intake.25 27 In this study, the rise in PYY and
GLP-1 was apparent between 240 min and 420 min following
oral administration of the inulin-propionate ester, and reached
levels similar to those observed following a 1000 kcal meal.39
Such a rise did not occur following ingestion of the inulin-
control, suggesting that it is a specific effect of the inulin-
propionate ester rather than the standardised 356 kcal lunch
provided in both trials. This would suggest that compared with
the inulin-propionate ester, a 10 g dose of inulin-control does
not raise colonic SCFA to a sufficient concentration to stimulate
gut hormone release.40 Recent evidence suggests the colonic
microbiota adapt rapidly to a change in substrate availability.41
Data from batch culture experiments demonstrated that inulin-
control and inulin-propionate ester stimulate changes to the gut
microbiota, although only inulin-control had a selective effect
on Bifidobacterium. This would suggest that the observed short-
term effects on appetite regulation were independent of altera-
tions to gut microbial composition.
Longitudinal studies demonstrate that adults gain weight grad-
ually through middle age, with an average yearly weight gain of
0.3–0.8 kg.6–9 This accumulation of weight would result from a
small daily positive energy balance of around 50–100 kcal.10
The 14% (162 kcal) reduction in food intake observed follow-
ing acute administration of 10 g/day inulin-propionate ester
would have a significant impact on weight gain and health if sus-
tained over the long term.42 We therefore investigated if long-
term elevation of colonic propionate would prevent weight gain
by conducting a 24 week randomised controlled trial of inulin-
propionate ester supplementation in overweight middle-aged
adults. We demonstrated lower weight gain in the inulin-
propionate ester group, with significantly fewer volunteers
gaining ≥3% or ≥5% body weight. This was coupled with a
reduced gain in intra-abdominal adipose tissue compared with
the inulin-control group and prevention of the deterioration of
postprandial glucose response. Furthermore, long-term eleva-
tions in colonic propionate production reduced IHCL content
in subjects meeting the diagnostic criteria for NAFLD. A reduc-
tion in IHCL is a reproducible finding in rodents fed a high
level of fermentable dietary fibre,16 43 however the mechanism
behind this is not well understood. Intra-abdominal adipose
tissue and NAFLD are regarded as major risk factors in the
development of insulin resistance and type 2 diabetes.44
Interestingly, in this long-term study we were unable to detect
any change in PYY or GLP-1 release following ingestion of the
inulin-propionate ester compared with inulin-control, in contrast
to our acute administration studies. This suggests that there may
be a desensitisation of the FFAR2/3 receptor response over time
and that the beneficial effects of long-term inulin-propionate
ester supplementation may not be mediated by PYY and GLP-1.
However, subjective ratings of postprandial appetite were signifi-
cantly reduced within the inulin-propionate ester group and we
observed a trend towards a significant decrease in food intake of
8.7% (73 kcal), suggesting that propionate may influence appe-
tite and energy intake via mechanisms unrelated to PYYor GLP-1
release. It has been demonstrated that propionate can stimulate
leptin release through activation of FFAR2 on adipocytes,45
although we did not observe any changes in circulating leptin
concentrations following acute or long-term supplementation
with inulin-propionate ester. Recent reports suggest that propion-
ate could also have a positive effect on energy balance and body
weight independent of energy intake. An investigation observed
weight loss in germ-free mice transplanted with microbiota from
animals which had undergone gastric bypass surgery. The
reduced body weight was associated with increased microbial
production of propionate, but no differences in energy intake
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were observed.5 In addition, when the intestines of germ-free
mice are transplanted with microbiota from an obese or lean
human twin it was found that animals receiving the transplant
from the lean twin donor developed decreased lower body mass
and adiposity level compared with those receiving the transplant
from the obese twin, despite comparable energy intake.4 The
inhibition of adipose tissue accumulation observed in the lean
twin transplanted mice was associated with greater amounts of
propionate produced by the gut microbiota. The outcome of
these investigations could be attributed to the observation that
propionate promotes sympathetic activity via FFAR3, resulting in
elevated energy expenditure.46 Furthermore, SCFA activation of
FFAR2 has been shown to reduce the sensitivity of murine adipo-
cytes to insulin, leading to reduced lipid clearance by adipocytes
and to increased energy expenditure, with preferential oxidation
of lipid.47 Propionate has also been shown to stimulate a gut–
brain circuit via FFAR3 in the portal vein wall, leading to the
induction of intestinal gluconeogenesis (IGN) gene expression.48
The authors suggest that the glucose released by IGN is detected
by a portal vein glucose sensor that transmits its signal to the
brain by the peripheral nervous system to promote beneficial
effects on energy homoeostasis. Using a rodent-model it was
found that upregulation of IGN by propionate reduced body
weight gain and adiposity independent of food intake. These
reports indicate that propionate can contribute to energy hom-
oeostasis through effects on numerous cellular metabolic path-
ways and receptor-mediated mechanisms and provide a potential
explanation for the differences in body weight gain and adiposity
observed between supplementation groups in the long-term
study. Additional investigations are therefore warranted to clarify
the effects of long-term supplementation with the inulin-
propionate ester on energy expenditure and the metabolic and
neural pathways that regulate substrate oxidation. Given that
acutely elevating colonic propionate increases plasma PYY and
GLP-1 levels and inhibits energy intake in healthy subjects, and
that this effect on gut hormone release appears to be lost follow-
ing long-term supplementation while a reduction in body weight
gain is maintained, the short-term and long-term effects of
colonic propionate may have divergent underlying biological
mechanisms.
A possible limitation of our study design would be the choice
of inulin as a control for the inulin-propionate ester. Inulin was
used as a control to specifically account for any effects that may
derive from colonic fermentation of inulin itself, rather than the
release of the esterified propionate. As our in vitro faecal fer-
mentation data demonstrates, the levels of propionate produced
by the inulin-control are relatively small compared with those
produced by the inulin-propionate ester, but the production of
acetate and butyrate are comparable. Previous studies have
shown that much larger doses of inulin-type fructans (>30 g/
day) are required to modulate gut hormone release and appetite
regulation than used as a control in the present design.40 49 It is
therefore unlikely that the 10 g/day dose of inulin used as a
control is masking any effects of the inulin-propionate ester on
our primary and secondary outcome measures. Nevertheless,
the SCFA production from 10 g/day inulin may be sufficient to
explain some of the significant long-term changes observed
within the inulin-control group, particularly the reductions in
fasting cholesterol.50
In summary, these studies provide the first direct evidence
that colonic propionate can acutely reduce energy intake and
prevent long-term weight gain in humans. The present results
support a role specifically for colonic propionate in weight man-
agement and may provide a molecular explanation of recent
data that have observed changes in the gut microbiome and
associated SCFA production profiles in weight loss. In humans,
the beneficial actions of propionate appear to be mediated by
different mechanisms in the short term compared with the long
term, which warrants further study. Optimum delivery of propi-
onate to the colon through selection of propiogenic components
of the diet may represent a novel route to improve weight man-
agement at the population level.
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